The mechanism, briefly
Wegovy is semaglutide — it acts on a single gut hormone, GLP-1. Mounjaro is tirzepatide, the first medicine to act on two, GIP and GLP-1, at once. In trials, tirzepatide has produced the largest average weight reduction of any licensed GLP-1 to date. That doesn't automatically make it "better" for you — it makes it a strong option to weigh.
What actually decides it
- Your medical history and any interactions our clinicians flag.
- How your body tolerates the first weeks — response is individual.
- Availability, cadence, and cost that fit your routine.
- Your own preference, once you understand the trade-offs.
Why we don't push one over the other
A checkbox website will happily sell you whichever it has most of. We'd rather start you on the medicine that suits your history and adjust if your body says otherwise. Switching is possible and safe when it's clinically sensible — which is exactly why an ongoing relationship beats a one-off transaction.
- Wegovy = semaglutide (single-hormone). Mounjaro = tirzepatide (dual-hormone).
- Tirzepatide shows the largest average weight loss in trials — but individual response varies.
- The right choice is a clinical conversation, not a default.
This article is general information, not medical advice, and doesn't replace a consultation. Whether a treatment is right for you — and at what dose — is a decision made with a PPRX clinician who reviews your history.